Back to results
US 11,890,336 B2Granted
Francisella glycoconjugate vaccines
AssigneeLondon School of Hygiene and Tropical Medicine
InventorsBrendan Wren, Jon Cuccui, Madeleine Moule
Life of this patent
Estimating the term…
Abstract
The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.
Claims18
A vaccine or immunogenic composition, comprising:
- a carrier polypeptide comprising at least 95% identity over the full length of the amino acid sequence of SEQ ID NO:
- 3 and
- an O-antigen antigenic polysaccharide isolated from Francisella crosslinked to the carrier polypeptide,
- wherein the O-antigen antigenic polysaccharide comprises 4)-α-D-GalNAcAN-(1-4)-α-D-GalNAcAN-(1-3)-β-D-GlcNAc-(1-2)-β-D-Qui4NFm-(1-), and
- wherein GalNacAN is 2-acetomido-2-deoxy-O-D-galacturonamide, Qui4NFm is 4,6-dideoxy-4-formamido-D-glucose, and the reducing end group GlcNAc is N-acetyl glucosamine.
2 more elements
An antigenic polypeptide, comprising:
- a carrier polypeptide comprising at least 95% identity over the full length amino acid sequence of SEQ ID NO:
- 3, and
- an O-antigen antigenic polysaccharide isolated from Francisella crosslinked to the carrier polypeptide;
- wherein the O-antigen comprises
- 4)-α-D-GalNAcAN-(1-4)-α-D-GalNAcAN-(1-3)-β-D-GlcNAc-(1-2)-β-D-Qui4NFm-(1-), and
- wherein GalNacAN is 2-acetomido-2-deoxy-O-D-galacturonamide, Qui4NFm is 4,6-dideoxy-4-formamido-D-glucose, and the reducing end group GlcNAc is N-acetyl glucosamine.
3 more elements
A vaccine or immunogenic composition, comprising:
- a carrier polypeptide comprising the amino acid sequence of SEQ ID NO:
- 3, and
- an O-antigen antigenic polysaccharide isolated from Francisella and crosslinked to said carrier polypeptide, wherein the O-antigen is 4)-α-D-GalNAcAN-(1-4)-α-D-GalNAcAN-(1-3)-β-D-GlcNAc-(1-2)-β-D-Qui4NFm-(1-), wherein GalNacAN is 2-acetomido-2-deoxy-O-D-galacturonamide, Qui4NFm is 4,6-dideoxy-4-formamido-D-glucose, and the reducing end group GlcNAc is N-acetyl glucosamine.
An antigenic polypeptide, comprising:
- a carrier polypeptide comprising the amino acid sequence of SEQ ID NO:
- 3, and
- an O-antigen antigenic polysaccharide isolated from Francisella and crosslinked to the carrier polypeptide, wherein the O-antigen is 4)-α-D-GalNAcAN-(1-4)-α-D-GalNAcAN-(1-3)-β-D-GlcNAc-(1-2)-β-D-Qui4NFm-(1-), wherein GalNacAN is 2-acetomido-2-deoxy-O-D-galacturonamide, Qui4NFm is 4,6-dideoxy-4-formamido-D-glucose, and the reducing end group GlcNAc is N-acetyl glucosamine.
Dependencies are inferred from the claim text.